Unicycive Therapeutics (UNCY) director granted 126,300 RSUs as equity pay

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Kenkare-Mitra Sara reported acquisition or exercise transactions in this Form 4 filing.

Unicycive Therapeutics director Sara Kenkare-Mitra received two equity awards in the form of restricted stock units. On May 14, 2026, she was granted 42,100 RSUs that vest in three equal annual installments and 84,200 RSUs that vest after one year, all settling in common stock and tied to continued service with the company. Following these grants, she holds 126,300 RSUs directly as part of her compensation, with no open-market share purchases or sales reported.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kenkare-Mitra Sara

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	84,200	$0.00	--
Grant/Award	Restricted Stock Units	42,100	$0.00	--

Holdings After Transaction: Restricted Stock Units — 84,200 shares (Direct, null)

Footnotes (1)

Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer. Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer.

Key Figures

RSU Award size: 42,100 RSUs Annual RSU Award size: 84,200 RSUs Total RSUs held after grants: 126,300 RSUs

3 metrics

RSU Award size 42,100 RSUs Grant of restricted stock units vesting over three years

Annual RSU Award size 84,200 RSUs Annual restricted stock unit grant vesting after one year

Total RSUs held after grants 126,300 RSUs Director’s direct RSU holdings following May 14, 2026 awards

Key Terms

Restricted Stock Units, RSU Award, Annual RSU Award

3 terms

Restricted Stock Units financial

"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSU Award financial

"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"

Annual RSU Award financial

"Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock"

Form 4 Insider Transactions: What Each Field Means →

05/21/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kenkare-Mitra Sara

(Last)

(First)

(Middle)

C/O UNICYCIVE THERAPEUTICS, INC.

1975 W. EL CAMINO REAL SUITE 204

(Street)

MOUNTAIN VIEW

CALIFORNIA

94040

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Unicycive Therapeutics, Inc. [ UNCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	05/14/2026		A		84,200		⁽¹⁾	⁽¹⁾	Common Stock	84,200	$0	84,200	D
Restricted Stock Units	$0	05/14/2026		A		42,100		⁽²⁾	⁽²⁾	Common Stock	42,100	$0	126,300	D

Explanation of Responses:

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

2. Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer.

	/s/ Sara Kenkare-Mitra	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Unicycive Therapeutics (UNCY) disclose for Sara Kenkare-Mitra?

Unicycive Therapeutics reported that director Sara Kenkare-Mitra received two grants of restricted stock units on May 14, 2026. These awards are equity compensation, not open-market trades, and will settle in shares of Unicycive common stock as they vest over time.

How many restricted stock units did Sara Kenkare-Mitra receive from Unicycive Therapeutics (UNCY)?

Sara Kenkare-Mitra received a total of 126,300 restricted stock units from Unicycive Therapeutics. One award covers 42,100 RSUs and the other 84,200 RSUs, each convertible into common stock upon vesting, subject to her continued service with the company.

What are the vesting terms of the new Unicycive Therapeutics (UNCY) RSU awards?

The 42,100-unit RSU Award vests in three equal installments on each anniversary of the May 14, 2026 grant date. The 84,200-unit Annual RSU Award vests in full one year after the grant date, with both awards conditioned on Sara Kenkare-Mitra’s continued service.

Did Sara Kenkare-Mitra buy or sell Unicycive Therapeutics (UNCY) shares in this Form 4?

The Form 4 shows no open-market purchases or sales by Sara Kenkare-Mitra. Instead, it reports compensation-related grants of restricted stock units with a transaction code A, indicating awards that will convert into common shares as vesting conditions are satisfied.

How many Unicycive Therapeutics (UNCY) RSUs does Sara Kenkare-Mitra hold after these grants?

After the reported grants, Sara Kenkare-Mitra directly holds 126,300 restricted stock units. Each RSU represents a right to receive one share of Unicycive common stock, subject to the specific vesting schedules and her continued service with the company.